Astellas/Boehringer Get Flomax Market Exclusivity Extension Through Pediatric Study
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Astellas Pharma announced that U.S. marketing partner Boehringer Ingelheim has obtained six-month pediatric exclusivity for blockbuster benign prostate hyperplasia drug Flomax (tamsulosin). The Flomax substance patent expires in October, and the period of market exclusivity will now be extended to April 2010
You may also be interested in...
Astellas Submits Pediatric Data To U.S. FDA For Flomax Exclusivity; Announces JV With Maxygen
TOKYO - Astellas Pharma July 1 said its U.S. licensee for Flomax (tamsulosin), Boehringer Ingelheim Pharmaceuticals submitted data to U.S. FDA from a study on pediatric patients with neurogenic bladders - apparently to fend off generics offerings when the drug's patent protection expires later this year
Astellas, Boehringer Sue Impax For Prostate Drug Patent Infringement
TOKYO - Moving in concert with the Japanese government's policy to toughen intellectual property rights protection, Astellas, jointly with Boehringer Ingelheim Pharmaceuticals, filed a patent infringement lawsuit in the United States against Impax Laboratories for Astellas' prostate treatment drug, the company announced July 22
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum